161 related articles for article (PubMed ID: 12955445)
1. [Relative contraindication of latanoprost in iris tumors with secondary glaucoma].
Fröhlich SJ; Mueller AJ; Kampik A
Ophthalmologe; 2003 Aug; 100(8):633-8. PubMed ID: 12955445
[TBL] [Abstract][Full Text] [Related]
2. Latanoprost-induced iris heterochromia and open-angle glaucoma: a clinicopathologic report.
Tsai JC; Sivak-Callcott JA; Haik BG; Zhang J; McLean IW
J Glaucoma; 2001 Oct; 10(5):411-3. PubMed ID: 11711840
[TBL] [Abstract][Full Text] [Related]
3. Iris cyst secondary to latanoprost mimicking iris melanoma.
Browning DJ; Perkins SL; Lark KK
Am J Ophthalmol; 2003 Mar; 135(3):419-21. PubMed ID: 12614778
[TBL] [Abstract][Full Text] [Related]
4. Histology and fine structure of the iris and outflow system following latanoprost therapy.
Grierson I; Pfeiffer N; Cracknell KP; Appleton P
Surv Ophthalmol; 2002 Aug; 47 Suppl 1():S176-84. PubMed ID: 12204715
[TBL] [Abstract][Full Text] [Related]
5. Iridial pigmentation induced by latanoprost ophthalmic solution in Japanese glaucoma patients.
Chiba T; Kashiwagi K; Kogure S; Abe K; Shibuya T; Furuichi M; Iijima H; Tsukahara S
J Glaucoma; 2001 Oct; 10(5):406-10. PubMed ID: 11711839
[TBL] [Abstract][Full Text] [Related]
6. Latanoprost : an update of its use in glaucoma and ocular hypertension.
Perry CM; McGavin JK; Culy CR; Ibbotson T
Drugs Aging; 2003; 20(8):597-630. PubMed ID: 12795627
[TBL] [Abstract][Full Text] [Related]
7. Latanoprost: experience of 2-year treatment in Scandinavia.
Alm A; Widengård I
Acta Ophthalmol Scand; 2000 Feb; 78(1):71-6. PubMed ID: 10726794
[TBL] [Abstract][Full Text] [Related]
8. Iris cyst secondary to latanoprost mimicking iris melanoma.
Sodhi PK
Am J Ophthalmol; 2003 Oct; 136(4):780; author reply 780-1. PubMed ID: 14516849
[No Abstract] [Full Text] [Related]
9. Incidence and severity of iris pigmentation on latanoprost-treated glaucoma eyes.
Chou SY; Chou CK; Kuang TM; Hsu WM
Eye (Lond); 2005 Jul; 19(7):784-7. PubMed ID: 15359238
[TBL] [Abstract][Full Text] [Related]
10. Incidence of a latanoprost-induced increase in iris pigmentation in Japanese eyes.
Latanoprost-Induced Iris Pigmentation Study Group
Jpn J Ophthalmol; 2006; 50(2):96-9. PubMed ID: 16604382
[TBL] [Abstract][Full Text] [Related]
11. A study of iridectomy histopathologic features of latanoprost- and non-latanoprost-treated patients.
Albert DM; Gangnon RE; Zimbric ML; Damico CM; Fisher MR; Gleiser J; Grossniklaus HE; Green WR
Arch Ophthalmol; 2004 Nov; 122(11):1680-5. PubMed ID: 15534130
[TBL] [Abstract][Full Text] [Related]
12. Travoprost compared with latanoprost and timolol in patients with open-angle glaucoma or ocular hypertension.
Netland PA; Landry T; Sullivan EK; Andrew R; Silver L; Weiner A; Mallick S; Dickerson J; Bergamini MV; Robertson SM; Davis AA;
Am J Ophthalmol; 2001 Oct; 132(4):472-84. PubMed ID: 11589866
[TBL] [Abstract][Full Text] [Related]
13. Assessment of chamber angle pigmentation during longterm latanoprost treatment for open-angle glaucoma.
Nakamura Y; Nakamura Y; Morine-Shinjo S; Sakai H; Sawaguchi S
Acta Ophthalmol Scand; 2004 Apr; 82(2):158-60. PubMed ID: 15043533
[TBL] [Abstract][Full Text] [Related]
14. Effect of additive preoperative latanoprost treatment on the outcome of filtration surgery.
Berthold S; Pfeiffer N
Graefes Arch Clin Exp Ophthalmol; 2006 Aug; 244(8):1029-34. PubMed ID: 16341541
[TBL] [Abstract][Full Text] [Related]
15. A 5-year, randomized, open-label safety study of latanoprost and usual care in patients with open-angle glaucoma or ocular hypertension.
Goldberg I; Li XY; Selaru P; Paggiarino D
Eur J Ophthalmol; 2008; 18(3):408-16. PubMed ID: 18465724
[TBL] [Abstract][Full Text] [Related]
16. Latanoprost, a prostaglandin analog, for glaucoma therapy. Efficacy and safety after 1 year of treatment in 198 patients. Latanoprost Study Groups.
Camras CB; Alm A; Watson P; Stjernschantz J
Ophthalmology; 1996 Nov; 103(11):1916-24. PubMed ID: 8942890
[TBL] [Abstract][Full Text] [Related]
17. Meta-analysis of randomised controlled trials comparing latanoprost with timolol in the treatment of patients with open angle glaucoma or ocular hypertension.
Zhang WY; Po AL; Dua HS; Azuara-Blanco A
Br J Ophthalmol; 2001 Aug; 85(8):983-90. PubMed ID: 11466259
[TBL] [Abstract][Full Text] [Related]
18. The incidence and time-course of latanoprost-induced iridial pigmentation as a function of eye color.
Wistrand PJ; Stjernschantz J; Olsson K
Surv Ophthalmol; 1997 Feb; 41 Suppl 2():S129-38. PubMed ID: 9154289
[TBL] [Abstract][Full Text] [Related]
19. Two-year follow-up of latanoprost 0.005% monotherapy after changing from previous glaucoma therapies.
Bayer A; Weiler W; Oeverhaus U; Skrotzki FE; Stewart WC;
J Ocul Pharmacol Ther; 2004 Dec; 20(6):470-8. PubMed ID: 15684807
[TBL] [Abstract][Full Text] [Related]
20. A 12-month, randomized, double-masked study comparing latanoprost with timolol in pigmentary glaucoma.
Mastropasqua L; Carpineto P; Ciancaglini M; Gallenga PE
Ophthalmology; 1999 Mar; 106(3):550-5. PubMed ID: 10080213
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
